Influence of long-standing pulmonary arterial hypertension and its severity on pulmonary artery aneurysm development.


Journal

Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 07 01 2020
accepted: 27 03 2020
pubmed: 6 4 2020
medline: 15 12 2020
entrez: 6 4 2020
Statut: ppublish

Résumé

Pulmonary artery aneurysm (PAA) is a common finding in patients with long-term pulmonary arterial hypertension (PAH). The influence of PAH severity in the development of PAA remains unclear. We sought to determine whether PAA development is related to PAH severity and whether treatment optimization based on risk profile estimation is effective to stop pulmonary artery (PA) enlargement. This is a retrospective study of 125 PAH patients who underwent an imaging test (computed tomography or magnetic resonance) combined with a right heart catheterization within a six-month period. A multivariate analysis was performed to identify independent risk factors for PAA. Patients who underwent an additional imaging-test and RHC during follow-up were analyzed to evaluate changes on PA dimensions. PAA was diagnosed in 42 (34%) patients. PAA was more frequent in patients with congenital heart disease and toxic oil syndrome. PAH time-course showed to be an independent risk factor for PAA (HR 1.051, 95% CI 1.013-1.091, p = 0.008) whereas PAH severity did not. Twenty-six patients underwent a follow-up imaging-test and catheterization. After treatment optimization, a non-significant reduction of mean PA pressure was observed (58.5 mmHg [43.5-70.8] vs. 55.5 mmHg [47.5-66.3], p = 0.115) and a higher proportion of patients achieved a low-risk profile (19% vs. 35%, p = 0.157). However, the PA diameter significantly increased (40.4 ± 10.1 mm vs. 42.1 ± 9.6 mm; p = 0.003). PAA is a common condition in long-standing PAH but its development is not necessarily related to PAH severity. Despite stabilization after treatment optimization, a progressive PA dilatation was observed.

Identifiants

pubmed: 32248253
doi: 10.1007/s00380-020-01600-5
pii: 10.1007/s00380-020-01600-5
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1290-1298

Subventions

Organisme : Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares
ID : CB16/11/00502

Auteurs

Jorge Nuche (J)

CIBER de Enfermedades Cardiovasculars (CIBERCV), Madrid, Spain.
Department of Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avenida de Córdoba s/n, 28041, Madrid, Spain.
Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.

José Manuel Montero-Cabezas (JM)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Ana Lareo (A)

Department of Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avenida de Córdoba s/n, 28041, Madrid, Spain.

Sergio Huertas (S)

Department of Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avenida de Córdoba s/n, 28041, Madrid, Spain.
Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

Carmen Jiménez López-Guarch (C)

CIBER de Enfermedades Cardiovasculars (CIBERCV), Madrid, Spain.
Department of Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avenida de Córdoba s/n, 28041, Madrid, Spain.
Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.

Maite Velázquez Martín (M)

Department of Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avenida de Córdoba s/n, 28041, Madrid, Spain.

Sergio Alonso Charterina (S)

Deparment of Radiology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Yolanda Revilla Ostolaza (Y)

Deparment of Radiology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Juan F Delgado (JF)

CIBER de Enfermedades Cardiovasculars (CIBERCV), Madrid, Spain.
Department of Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avenida de Córdoba s/n, 28041, Madrid, Spain.
Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.

Fernando Arribas Ynsaurriaga (F)

CIBER de Enfermedades Cardiovasculars (CIBERCV), Madrid, Spain.
Department of Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avenida de Córdoba s/n, 28041, Madrid, Spain.
Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.

Pilar Escribano Subías (P)

CIBER de Enfermedades Cardiovasculars (CIBERCV), Madrid, Spain. pilar.escribano.subias@gmail.com.
Department of Cardiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avenida de Córdoba s/n, 28041, Madrid, Spain. pilar.escribano.subias@gmail.com.
Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. pilar.escribano.subias@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH